See the full story in the original article.
Read the original on Yahoo Finance ↗
Keywords
earningspharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related news
- Cencora, Inc. Q4 2026 Earnings Call Summary
- Pfizer Inc. Q3 2026 Earnings Call Summary
- Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?
Eli Lilly reported third-quarter revenue up 39% year over year to $24.4 billion, driven mainly by GLP-1 drugs: Mounjaro rose 65% to $10.7 billion and Zepbound rose 49% to $5.4 billion. Non-GAAP earnings per share were $7.48, up 7%, held back by acquisition-related expenses, but both revenue and earnings beat analyst estimates. The company raised its full-year 2026 revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion, and its shares jumped after the report. The article argues the GLP-1 market still has room to expand given low penetration, and views Lilly's pipeline, including retatrutide, as among the strongest in the field, while noting pricing pressure and competition from new medicines over the medium term.
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Biotech stocks rose last week and beat the broader market, with IBB up 5%, XBI up 4% and XLV up 3%, while SPY fell 0.6% and QQQ dropped 2%. This week, Vertex reports on Monday after the close, with second-quarter sales of $49.6 million for Journavx and $76.4 million for Casgevy. Pfizer (PFE) and Amgen (AMGN) report on Tuesday, Novo Nordisk (NVO) on Wednesday, and Moderna (MRNA) on Friday. Investors will watch Wegovy pill sales, whether Pfizer's newer medicines can offset weaker COVID-related sales, and updates on Amgen's MariTide and Moderna's personalized cancer vaccine. Cancer research will also be presented at the Society for Immunotherapy of Cancer's annual meeting, running November 4 to 8 in Phoenix.
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
- What Just Happened To Alnylam Stock?
Alnylam Pharmaceuticals (ALNY) stock fell 25.1% on Thursday, October 29, 2026, the day it reported third-quarter results, while the S&P 500 slipped 0.3%. Revenue beat estimates at $1.46 billion versus $1.43 billion, with product revenue up 52% to about $1.3 billion led by AMVUTTRA, though GAAP net income of $2.2 billion included a one-time non-cash tax benefit of about $1.9 billion. Management said it is "not yet satisfied with the underlying demand growth" and expects TTR product sales at the low end of its $4.2 billion to $4.5 billion range. It also said turning new prescribers into patient starts is taking longer than hoped, and 2027 product revenue guidance will come in mid-February. The decline stood apart from a 2.4% rise in the health care fund XLV, and the stock is down 63.9% over the past twelve months.
Related markets
Latest news
- AI data centers have a bigger problem than water
Host Ejaaz Ahamadeen argues that concerns about AI data centers' water use are overstated, noting that facilities now recycle the same water and that the author of an earlier viral claim later corrected herself. Citing a SemiAnalysis review, he says one or two In-N-Out restaurants use more water than Elon Musk's Colossus 2, one of the largest AI data centers. He says electricity demand is the more valid concern and points to Microsoft and, he believes, Meta pledging to cover and subsidize local electricity bills if they rise. He predicts the hyperscalers will simply pay those costs, though he says he will believe the pledges when he sees them.
- Sam Altman Says It's 'Fucking Annoying' His RAM Comments Were Taken Out of Context
OpenAI CEO Sam Altman said it was 'fucking annoying' that his comments about computer memory were taken out of context after Elon Musk mocked them. Altman had said it was 'quite terrible' for the world's limited DRAM supply to sit in home computers used 5% of the time, and he said he has long argued for more memory production. He briefly renamed his X account 'Ram Altman' in response to users' jokes. The remarks come amid a global memory shortage driven by AI data center demand, with contract prices for 16GB DDR5 chips reportedly rising from $8.70 in October 2025 to $48 in September 2026, an increase of more than 550%.
- Blockchain is ‘perfect solution’ for AI agent trust, VeChain CEO says
VeChain co-founder and CEO Sunny Lu said AI agents could drive blockchain's next adoption cycle, since autonomous agents would need systems to verify their identities and reputations, calling blockchain 'the perfect solution'. He spoke on Cointelegraph's Chain Reaction show while promoting VeWorld.ai, an agent-building platform that uses VeChain's blockchain. In his vision, agents would carry digital 'passports' within a decentralized credibility system that tracks their reputations and those of their creators, with smart contracts settling transactions between agents or with people. Lu also argued that agent-building tools could let non-developers turn their expertise into businesses, comparing this to mobile app stores, while Animoca Brands chairman Yat Siu warned that users risk building strategies around services they do not control.
- Apple cuts staff AI usage in scramble to rein in costs
Apple has restricted employees' AI use to cut costs. According to Bloomberg, daily usage caps for engineering staff were reduced from $300 (£223) to $200, and the company is reportedly considering lowering the engineering cap to $100 and cutting non-technical staff's daily budgets from $100 to $25. Apple joins other companies that have curbed AI spending, including Revolut, Accenture, Uber, Tesla, Microsoft and Meta, amid concerns about costs and productivity. The limits apply to 'tokens', units of AI consumption, even as Apple pushes staff to use more AI to boost productivity. The changes are among the first by CEO John Ternus, who succeeded Tim Cook in September, and the trend has raised concerns about the planned IPOs of Anthropic and OpenAI, with investors saying Anthropic may list at a valuation of $1.5tn or less, below earlier hopes of $2tn. Apple did not comment.
- Chinese AI lab Moonshot turned to Europe for Nvidia Blackwell access amid U.S. China curbs, sources tell CNBC
Moonshot AI, a Chinese AI lab that the White House said accessed Nvidia's Blackwell chips via a facility in Thailand, has reportedly sought access to such chips through data centers in Europe, according to CNBC sources. Talks this year reportedly covered renting capacity from non-Chinese neocloud operators, including clusters of 8,000 or more Blackwell GPUs for inference and possibly training. One source said Moonshot was proposed to pay 30% to 50% more upfront than a non-Chinese customer. U.S. export controls restrict shipments of Nvidia's most advanced chips to China, but remote access through overseas cloud services is not broadly regulated, and the Remote Access Security Act passed the House in January but has not cleared the Senate. The Financial Times reported that Nvidia told cloud providers to sell at least 51% of their services to non-Chinese customers. Moonshot and Nvidia did not respond to requests for comment.
- TSMC’s AI Opportunity Is Expanding. Here’s the Question That Matters for Its Stock Price
TSMC posted its third straight earnings beat, with third-quarter EPS of $4.60 against a $4.46 consensus and revenue of $46.72 billion, up 41.2% in dollar terms. It guided fourth-quarter revenue to $52.3 billion to $54.3 billion. Even so, shares fell 10.97% over the past month and closed at $406.13. CFO Wendell Huang said that if the company executes well, revenue growth will outpace capex growth. The 24/7 Wall St. price target is $516.16, implying 27.09% upside, with a bull case of $536.47 and a bear case of $432.68, and the article flags margin dilution from overseas fabs as a risk, with gross margin down 1.3 points sequentially and guided margins of 65% to 67%.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.